Literature DB >> 8290568

Functional analysis of myosin missense mutations in familial hypertrophic cardiomyopathy.

A J Straceski1, A Geisterfer-Lowrance, C E Seidman, J G Seidman, L A Leinwand.   

Abstract

To analyze potential functional consequences of myosin heavy chain (MHC) mutations identified in patients with familial hypertrophic cardiomyopathy (FHC), we have assessed the stability of the mutant MHCs and their ability to form thick filaments. Constructs encoding wild-type rat alpha MHC and seven corresponding FHC missense mutants were transfected into COS cells. Immunoblot analysis suggested that FHC mutations do not grossly alter protein stability. Wild-type alpha MHC transfected into COS cells forms structures previously shown to be arrays of thick filaments, which also resemble myosin structures observed early in differentiation of muscle cells. Surprisingly, up to 29% of COS cells transfected with the FHC mutants failed to form filamentous structures. To assess whether this phenotype was specific for the FHC mutants and not generalizable to any myosin mutation, COS cells were transfected with a construct encoding an MHC with a 168-amino acid deletion of the hinge/rod region. This deletion construct formed filamentous structures with the same frequency as wild-type MHC. Biochemical analysis of one FHC mutant (Arg-249-->Gln) demonstrates that the structures formed by the mutant are solubilized at a lower ionic strength than those formed by wild-type MHC. We conclude that although the FHC mutant MHC is not labile, its assembly properties may be impaired.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8290568      PMCID: PMC42994          DOI: 10.1073/pnas.91.2.589

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Mutagenesis of the putative fusion domain of the Semliki Forest virus spike protein.

Authors:  P Levy-Mintz; M Kielian
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation.

Authors:  A A Geisterfer-Lowrance; S Kass; G Tanigawa; H P Vosberg; W McKenna; C E Seidman; J G Seidman
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

3.  A molecular basis for familial hypertrophic cardiomyopathy: an alpha/beta cardiac myosin heavy chain hybrid gene.

Authors:  G Tanigawa; J A Jarcho; S Kass; S D Solomon; H P Vosberg; J G Seidman; C E Seidman
Journal:  Cell       Date:  1990-09-07       Impact factor: 41.582

4.  Full-length rat alpha and beta cardiac myosin heavy chain sequences. Comparisons suggest a molecular basis for functional differences.

Authors:  E M McNally; R Kraft; M Bravo-Zehnder; D A Taylor; L A Leinwand
Journal:  J Mol Biol       Date:  1989-12-05       Impact factor: 5.469

5.  Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk.

Authors:  W J McKenna; A J Camm
Journal:  Circulation       Date:  1989-11       Impact factor: 29.690

6.  Genetic dissection of Drosophila myofibril formation: effects of actin and myosin heavy chain null alleles.

Authors:  C J Beall; M A Sepanski; E A Fyrberg
Journal:  Genes Dev       Date:  1989-02       Impact factor: 11.361

Review 7.  Assembly processes in vertebrate skeletal thick filament formation.

Authors:  J S Davis
Journal:  Annu Rev Biophys Biophys Chem       Date:  1988

8.  Preparation and characterization of heavy meromyosin and subfragment 1 from vertebrate cytoplasmic myosins.

Authors:  J R Sellers; M S Soboeiro; K Faust; A R Bengur; E V Harvey
Journal:  Biochemistry       Date:  1988-09-06       Impact factor: 3.162

Review 9.  Hypertrophic cardiomyopathy.

Authors:  Z Sasson; H Rakowski; E D Wigle
Journal:  Cardiol Clin       Date:  1988-05       Impact factor: 2.213

10.  Overexpression of tau in a nonneuronal cell induces long cellular processes.

Authors:  J Knops; K S Kosik; G Lee; J D Pardee; L Cohen-Gould; L McConlogue
Journal:  J Cell Biol       Date:  1991-08       Impact factor: 10.539

View more
  8 in total

Review 1.  [Genetic causes of hypertrophic cardiomyopathy].

Authors:  H P Vosberg
Journal:  Med Klin (Munich)       Date:  1998-04-15

2.  Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart.

Authors:  W K Jones; I L Grupp; T Doetschman; G Grupp; H Osinska; T E Hewett; G Boivin; J Gulick; W A Ng; J Robbins
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

3.  R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level.

Authors:  K A Palmiter; M J Tyska; J R Haeberle; N R Alpert; L Fananapazir; D M Warshaw
Journal:  J Muscle Res Cell Motil       Date:  2000       Impact factor: 2.698

4.  Effects of pathogenic proline mutations on myosin assembly.

Authors:  Massimo Buvoli; Ada Buvoli; Leslie A Leinwand
Journal:  J Mol Biol       Date:  2011-12-06       Impact factor: 5.469

5.  Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy.

Authors:  O Roopnarine; L A Leinwand
Journal:  Biophys J       Date:  1998-12       Impact factor: 4.033

6.  The leukemic core binding factor beta-smooth muscle myosin heavy chain (CBF beta-SMMHC) chimeric protein requires both CBF beta and myosin heavy chain domains for transformation of NIH 3T3 cells.

Authors:  A Hajra; P P Liu; Q Wang; C A Kelley; T Stacy; R S Adelstein; N A Speck; F S Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

7.  The cardiac myosin heavy chain Arg-403-->Gln mutation that causes hypertrophic cardiomyopathy does not affect the actin- or ATP-binding capacities of two size-limited recombinant myosin heavy chain fragments.

Authors:  P Eldin; M Le Cunff; D Mornet; J J Leger
Journal:  Biochem J       Date:  1995-03-01       Impact factor: 3.857

Review 8.  Hypertrophic cardiomyopathy: a heart in need of an energy bar?

Authors:  Styliani Vakrou; M Roselle Abraham
Journal:  Front Physiol       Date:  2014-08-19       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.